Future oncology最新文献

Correction. 修正。

IF 2.6 4区医学

Future oncology Pub Date : 2025-07-31 DOI: 10.1080/14796694.2025.2541136

引用次数: 0

Serum sphingosine-1-phosphate levels are associated with brain metastasis in EGFR-mutant lung adenocarcinoma. 血清鞘氨醇-1-磷酸水平与egfr突变型肺腺癌脑转移相关

IF 2.6 4区医学

Future oncology Pub Date : 2025-07-31 DOI: 10.1080/14796694.2025.2539059

Gang Xu, Yajie Li, Bo An, Bo Pan, Lihua Shang, Yan Yu, Dexin Jia

{"title":"Serum sphingosine-1-phosphate levels are associated with brain metastasis in EGFR-mutant lung adenocarcinoma.","authors":"Gang Xu, Yajie Li, Bo An, Bo Pan, Lihua Shang, Yan Yu, Dexin Jia","doi":"10.1080/14796694.2025.2539059","DOIUrl":"https://doi.org/10.1080/14796694.2025.2539059","url":null,"abstract":"Aim: To investigate the association between serum sphingosine-1-phosphate (S1P) levels and brain metastasis in EGFR-mutant lung adenocarcinoma (LUAD).Methods: Serum S1P levels were analyzed in 103 LUAD patients. The baseline characteristics of the 103 patients in this study included the following: the overall cohort consisted of 50.49% males and 49.51% females. The average age of the cohort was 69.50 years (SD = 59.12). Regarding EGFR mutations, 52 patients (50.49%) had wild-type EGFR, 19 patients (18.45%) had EGFR Ex19Del, and 32 patients (31.07%) had the L858R mutation. Logistic regression models and competing risk Cox analyses were used to evaluate the association between S1P levels and brain metastasis. Kaplan-Meier curves assessed cumulative brain metastasis incidence over time.Results: Serum sphingosine-1-phosphate (SIP) levels were measured with the following results (mean ± SD): wild-type EGFR, 970.44 ± 344.37 nmol/L; Ex19Del, 1,246.41 ± 306.93 nmol/L; and L858R, 1,333.21 ± 385.08 nmol/L (p < 0.001). In EGFR-mutant patients, S1P levels were independently associated with increased risk of brain metastasis (OR = 8.2, p = 0.003; HR = 105, p < 0.001), whereas no significant association was observed in EGFR wild-type patients. Kaplan-Meier analysis revealed that high S1P levels were linked to earlier brain metastasis in EGFR-mutant patients (p = 0.0034). The relationship between S1P levels and brain metastasis was not significantly influenced by the presence of bone metastasis (p > 0.1).Conclusion: Elevated serum S1P levels are significantly associated with brain metastasis in EGFR-mutant LUAD patients. S1P may serve as a biomarker for brain metastasis risk and a potential therapeutic target.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-9"},"PeriodicalIF":2.6,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144753196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ESO-Shanghai 20: phase III clinical trial of anti-PD-1 therapy with local intervention for oligometastatic ESCC. ESO-Shanghai 20：局部干预抗pd -1治疗低转移性ESCC的III期临床试验

IF 2.6 4区医学

Future oncology Pub Date : 2025-07-30 DOI: 10.1080/14796694.2025.2534770

Guangmin Mao, Zhuocheng Xin, Qingsong Fan, Huijuan Zhu, Jinjun Ye, Long Zhou, Yufeng He, Benhua Xu, Cheng Chen, Zhijun Li, Xiaowei Gu, Xianfeng Li, Xiaomin Wang, Junjun Guo, Zhengyang Xu, Peng Wan, Yunxia Zhang, Fuzheng Zhang, Canhong Huang, Qiong Yi, Jiangqiong Huang, Shixiong Liang, Junqiang Chen, Yu Lin, Qingliang Fang, Yun Chen, Dashan Ai, Hongcheng Zhu, Shengnan Hao, Qi Liu, Kuaile Zhao

引用次数: 0

Association of exosomal miR17-92a cluster and target genes with breast cancer risk. 外泌体miR17-92a簇和靶基因与乳腺癌风险的关系

IF 2.6 4区医学

Future oncology Pub Date : 2025-07-29 DOI: 10.1080/14796694.2025.2539627

Ambreen Parvaiz, Azhar Mehmood, Muhammad Saeed, Mahmood Akhtar Kayani, Ishrat Mahjabeen

{"title":"Association of exosomal miR17-92a cluster and target genes with breast cancer risk.","authors":"Ambreen Parvaiz, Azhar Mehmood, Muhammad Saeed, Mahmood Akhtar Kayani, Ishrat Mahjabeen","doi":"10.1080/14796694.2025.2539627","DOIUrl":"https://doi.org/10.1080/14796694.2025.2539627","url":null,"abstract":"Background: The present study aimed to explore the roles of exosomal microRNAs (miR-17, miR-19b, and miR-92a) and two target genes (PTEN and TGFβR2) in breast cancer risk.Methods: Expression analysis was performed using real-time PCR in a study cohort of 500 patients and 500 age- and sex-matched healthy controls.Results: The selected miRNAs (miR-17, p < 0.01; miR-19b, p < 0.01; miR-92a, p < 0.01) and TGFβR2 (p < 0.01) revealed an upregulated expression pattern, whereas downregulation of PTEN (p < 0.05) was observed in cancer patients compared to controls. A significant upregulated expression of miR-17, miR-92a, and TGFβR2 was observed in advanced clinical stages, advanced T-stage, advanced N-stage, and advanced M-stage in breast cancer patients.Conclusions: These findings demonstrate the oncogenic potential of the selected miRNAs, contributing to breast carcinogenesis. Further analysis showed an association between the expression deregulation of the selected molecules and increased cell proliferation and metastasis. miR-17 and TGFβR2 showed good diagnostic potential with AUCs of 0.708 and 0.909, respectively.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-16"},"PeriodicalIF":2.6,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144729677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ABC-12: exploring the microbiome in patients with advanced biliary tract cancer in a first-line study of durvalumab (MEDI4736) in combination with cisplatin/gemcitabine. ABC-12：在durvalumab （MEDI4736）联合顺铂/吉西他滨的一线研究中探索晚期胆道癌患者的微生物组。

IF 2.6 4区医学

Future oncology Pub Date : 2025-07-29 DOI: 10.1080/14796694.2025.2539018

Eleni Vrana, Hayley Timmins, Ashley Osborne, Rebecca Cox, Harpreet Wasan, Yuk Ting Ma, Arvind Arora, Olusola Faluyi, Roopinder Gillmore, Pippa Corrie, Paul Miller, Seema Arif, Joanna Canham, Charlotte Martin, Muhammad Riaz, Tongtong Shi, Melissa Frizziero, Victoria Foy, Richard A Hubner, Helen Morement, John Bridgewater, Richard Adams, Juan W Valle, Mairéad G McNamara

{"title":"ABC-12: exploring the microbiome in patients with advanced biliary tract cancer in a first-line study of durvalumab (MEDI4736) in combination with cisplatin/gemcitabine.","authors":"Eleni Vrana, Hayley Timmins, Ashley Osborne, Rebecca Cox, Harpreet Wasan, Yuk Ting Ma, Arvind Arora, Olusola Faluyi, Roopinder Gillmore, Pippa Corrie, Paul Miller, Seema Arif, Joanna Canham, Charlotte Martin, Muhammad Riaz, Tongtong Shi, Melissa Frizziero, Victoria Foy, Richard A Hubner, Helen Morement, John Bridgewater, Richard Adams, Juan W Valle, Mairéad G McNamara","doi":"10.1080/14796694.2025.2539018","DOIUrl":"https://doi.org/10.1080/14796694.2025.2539018","url":null,"abstract":"Until recently, cisplatin/gemcitabine was standard of care for the first-line treatment of patients with advanced biliary tract cancer (BTC). The addition of durvalumab, an immune checkpoint inhibitor, to the combination of cisplatin/gemcitabine has demonstrated an overall survival (OS) benefit and is now a standard of care first-line treatment option. BTCs exhibit immunogenic features may develop through an accumulation of genetic and epigenetic alterations, and can be influenced by microbial exposure. Microbiota can influence inflammation and immunity, and its disruption may impair tumor response to immunotherapy and chemotherapy. Here, the rationale and design of the multi-center, single-arm ABC-12 trial (ISRCTN11210442) is described, which investigates the role of the microbiome in patients with advanced BTC in a first-line study of durvalumab (MEDI4736) in combination with cisplatin/gemcitabine. The primary objective is to determine the difference in baseline alpha diversity between \"responders\" (partial or complete response) and \"non-responders\" at 18 weeks (RECIST 1.1) in patients treated with cisplatin/gemcitabine/durvalumab. Secondary objectives include investigating the association between microbiome parameters and objective response rate, tumor control (partial, complete response, and stable disease), progression-free and OS, and investigating the interaction between treatment effect and microbiome parameters on clinical outcomes.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-9"},"PeriodicalIF":2.6,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144729746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma. SGNDV-001：地西他单维多汀联合派姆单抗治疗表达her2的局部晚期或转移性尿路上皮癌

IF 2.6 4区医学

Future oncology Pub Date : 2025-07-29 DOI: 10.1080/14796694.2025.2535280

Thomas B Powles, Enrique Grande, Nimira Alimohamed, Niara Oliveira, Srikala S Sridhar, Alexandra Drakaki, Ravindran Kanesvaran, Yohann Loriot, Andrea Necchi, Sonia Franco, Dingfeng Jiang, Kristel Apolinario, Wei Zhang, Matthew D Galsky

{"title":"SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma.","authors":"Thomas B Powles, Enrique Grande, Nimira Alimohamed, Niara Oliveira, Srikala S Sridhar, Alexandra Drakaki, Ravindran Kanesvaran, Yohann Loriot, Andrea Necchi, Sonia Franco, Dingfeng Jiang, Kristel Apolinario, Wei Zhang, Matthew D Galsky","doi":"10.1080/14796694.2025.2535280","DOIUrl":"https://doi.org/10.1080/14796694.2025.2535280","url":null,"abstract":"Introduction: Platinum-based chemotherapy for the treatment of locally advanced or metastatic urothelial carcinoma (la/mUC), has been the first-line standard of care for many decades. Enfortumab vedotin, an antibody-drug conjugate, combined with pembrolizumab, a programmed death 1 (PD-1) inhibitor, recently demonstrated improved efficacy versus chemotherapy in la/mUC. Since 60%-80% of patients with UC have tumors expressing human epidermal growth factor receptor 2 (HER2), HER2-directed vedotin-based antibody-drug conjugates may also be beneficial in la/mUC.Patients and methods: The phase 3 trial SGNDV-001 (C5731001; NCT05911295) is evaluating disitamab vedotin (HER2-directed antibody-drug conjugate) with pembrolizumab compared with chemotherapy in treatment-naive patients with HER2-expressing la/mUC. Dual primary endpoints are progression-free survival (per blinded independent central review) and overall survival. Potential synergistic effects of disitamab vedotin and pembrolizumab could establish this combination as a novel therapeutic option for HER2-expressing la/mUC.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-8"},"PeriodicalIF":2.6,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144729679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular testing, treatment patterns, and outcomes in EGFR-mutated non-small cell lung cancer: the PISCES study. egfr突变的非小细胞肺癌的分子检测、治疗模式和结果：双鱼座研究

IF 2.6 4区医学

Future oncology Pub Date : 2025-07-28 DOI: 10.1080/14796694.2025.2529094

Panwen Tian, Lin Wu, Chengzhi Zhou, Jie Tan, Ke Wang, Feng Luo, Yongmei Liu, Yubiao Guo, Yinyin Li, Zhe Liu, Youling Gong, Yongsheng Wang, Jinghong Xian, Weimin Li

{"title":"Molecular testing, treatment patterns, and outcomes in EGFR-mutated non-small cell lung cancer: the PISCES study.","authors":"Panwen Tian, Lin Wu, Chengzhi Zhou, Jie Tan, Ke Wang, Feng Luo, Yongmei Liu, Yubiao Guo, Yinyin Li, Zhe Liu, Youling Gong, Yongsheng Wang, Jinghong Xian, Weimin Li","doi":"10.1080/14796694.2025.2529094","DOIUrl":"https://doi.org/10.1080/14796694.2025.2529094","url":null,"abstract":"Background: This study investigated molecular testing, treatment patterns, and prognosis in Chinese patients who progressed from first-line (1 L), epidermal growth factor receptor -tyrosine kinase inhibitors (EGFR-TKIs) therapy, highlighting limited real-world data on clinical practice.Methods: Consecutive eligible patients were prospectively enrolled in 16-centers in China. The primary endpoints were second-line (2 L) treatment patterns and clinical outcomes, including median progression-free survival (mPFS) and median overall survival (mOS) from 2 L treatment.Results: Overall, 300 patients were enrolled in the study, and among them, 291 patients were included in the Full Analysis Set, and 213(73.2%) underwent molecular testing, after progression from 1 L therapy. 30.5% (65/213) had tissue samples, while 66.7% (142/213) had plasma samples. In tissue and plasma samples, T790M positive rates were 53.8% and 43.7%, respectively. mPFS and mOS for patients with T790M positive who received third generation (3 G) EGFR-TKIs as 2 L therapy were 14.7 months and 32.0 months, respectively. The mPFS for patients with T790M negative who received 3 G EGFR-TKIs, prior EGFR-TKIs plus local therapy, and chemotherapy as 2 L therapy were 7.6 months, 10.2 months, and 4.9 months, respectively. The corresponding mOS for these patients were 21.2 months, 16.6 months, and 15.0 months, respectively. No new safety signal emerged.Conclusions: Patients with acquired resistance to first generation (1 G)/second generation (2 G) EGFR-TKIs receiving 3 G EGFR-TKIs, especially T790M positive, showed better clinical outcomes after molecular testing.Clinical trial registration: The study has been registered at ClinicalTrials.gov (NCT04207775).","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-11"},"PeriodicalIF":2.6,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144729678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Phase 1 study of the novel GCN2 kinase activator NXP800 in patients with advanced cholangiocarcinoma. 新型GCN2激酶激活剂NXP800在晚期胆管癌患者中的一期研究

IF 2.6 4区医学

Future oncology Pub Date : 2025-07-28 DOI: 10.1080/14796694.2025.2539611

Hendrien Kuipers, Joseph J Larson, Caitlin B Conboy, Daniel H Ahn, Tanios Bekaii-Saab, Christina Wu, Mohamad Bassam Sonbol, Sumera I Ilyas, Gregory J Gores, Rory L Smoot, Mitesh J Borad

引用次数: 0

COLUMBUS part 1-7-year results for encorafenib and binimetinib in BRAF V600-mutant melanoma. 哥伦布部分1-7年的结果：encorafenib和binimetinib治疗BRAF v600突变黑色素瘤。

IF 2.6 4区医学

Future oncology Pub Date : 2025-07-24 DOI: 10.1080/14796694.2025.2536459

Dirk Schadendorf

引用次数: 0

Evaluation of implementation of evolving practice patterns in the first-line treatment of patients with metastatic non-small cell lung cancer in Turkiye (ESTIMATE): a national, multicenter, retrospective, real-world evidence study. 评估土耳其转移性非小细胞肺癌患者一线治疗中不断发展的实践模式的实施情况（ESTIMATE）：一项全国性、多中心、回顾性、真实世界证据研究。

IF 3 4区医学

Future oncology Pub Date : 2025-07-24 DOI: 10.1080/14796694.2025.2527477

Mehmet Ali Nahit Sendur, Nuri Karadurmus, Irfan Cicin, Mahmut Gumus, Umut Demirci, Ozgur Ozyilkan, Muhammet Ali Kaplan, Sema Sezgin Goksu, Feyyaz Ozdemir, Cagatay Arslan, Basak Oyan Uluc, Erdem Goker, Muhammed Mustafa Oksuzokyar, Yasemin Esen, Mert Batum, Milan van Rheenan, Bernadette Poellinger

{"title":"Evaluation of implementation of evolving practice patterns in the first-line treatment of patients with metastatic non-small cell lung cancer in Turkiye (ESTIMATE): a national, multicenter, retrospective, real-world evidence study.","authors":"Mehmet Ali Nahit Sendur, Nuri Karadurmus, Irfan Cicin, Mahmut Gumus, Umut Demirci, Ozgur Ozyilkan, Muhammet Ali Kaplan, Sema Sezgin Goksu, Feyyaz Ozdemir, Cagatay Arslan, Basak Oyan Uluc, Erdem Goker, Muhammed Mustafa Oksuzokyar, Yasemin Esen, Mert Batum, Milan van Rheenan, Bernadette Poellinger","doi":"10.1080/14796694.2025.2527477","DOIUrl":"https://doi.org/10.1080/14796694.2025.2527477","url":null,"abstract":"Background: This national, multicenter, retrospective, non-interventional real-world evidence study aimed to address patient characteristics and systemic treatment practices of metastatic non-small cell lung cancer (mNSCLC) patients in Türkiye.Research design and methods: Over 6 months, 636 adults with mNSCLC at 12 Turkish oncology centers provided retrospective data.Results: Adenocarcinoma was the most common histology, with 95% having distant bone metastases and 64.8% having no comorbidities. The most frequently administered first-line therapy was combination chemotherapy followed by targeted therapy and immunotherapy. Overall, 55.5-69.3% of patients were tested for ALK, EGFR, ROS1, and PD-L1.Conclusions: Biomarker screening in mNSCLC patients in Türkiye was suboptimal compared to other countries, especially in public hospitals.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-11"},"PeriodicalIF":3.0,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0